ERBB2 and breast carcinoma: 7. Kaufman PA, Toi M, Neven P, Sohn J, Grischke EM, Andre V, et al. Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. Oncologist. 2020;25:e243-e51.